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the timing of intussusception relative to vaccina-
tion, a comparison of intussusception rates is not 
required. Also, the underidentification of intus-
susception cases would not bias our results unless 
we selectively missed cases of intussusception 
immediately after vaccination; we do not believe 
that this occurred.
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Diagnosis and Management of the Antiphospholipid Syndrome
To the Editor: In their review article, Garcia and 
Erkan (May 24 issue)1 describe current and future 
therapies in the prevention and treatment of 
thrombosis in patients with the antiphospholipid 
syndrome (APS). Direct oral anticoagulant therapy 
is mentioned as a possible therapeutic approach 
on the basis of the results of a randomized, con-
trolled trial.2 However, there is recent evidence 
that direct oral anticoagulants are less effective 
than warfarin in the prevention of recurrent 
thrombosis in patients with a high-risk profile 
(i.e., those who are triple-positive for lupus anti-
coagulant, anticardiolipin antibodies, and anti–
β2-glycoprotein I antibodies). We retrospectively 
observed a higher rate of recurrent thrombosis 
(particularly arterial thrombosis) among patients 
who received rivaroxaban than among those who 
received warfarin (42% vs. 7%).3 Moreover, an Ital-
ian randomized, controlled trial that compared 
rivaroxaban with warfarin in patients with APS 
who were triple-positive for lupus anticoagulant, 
anticardiolipin antibodies, and anti–β2-glycopro-
tein I antibodies (Rivaroxaban in Thrombotic 
Antiphospholipid Syndrome [TRAPS]; Clinical-
Trials.gov number, NCT02157272) closed prema-
turely in January 2018 because of an excess of 
thrombotic events in the group that received 
rivaroxaban. Hence, direct oral anticoagulants 
do not seem to be effective in high-risk patients 
with APS, and further studies to evaluate alterna-
tive therapeutic approaches (e.g., anticoagulant 
plus antiplatelet agents) are warranted.
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To the Editor: Garcia and Erkan state that 
catastrophic APS is difficult to distinguish from 
other thrombotic microangiopathies. We suggest 
that catastrophic APS is in fact the coexistence of 
APS and thrombotic thrombocytopenic purpura 
(TTP). The coexistence of TTP with other dis-
eases, such as systemic lupus erythematosus, is 
well recognized.1,2 Since the recommendation was 
made to add plasma exchange and rituximab 
therapy to anticoagulation, mortality among pa-
tients with so-called catastrophic APS has de-
creased.3,4 Acceptance of the view that TTP is 
caused by APS would allow physicians to initiate 
early therapy that could improve the prognosis of 
both diseases. Are we in fact dealing with an 
uncommon manifestation of APS or with two 
different diseases?
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To the Editor: In their review, Garcia and Erkan 
refer to the lack of population-based studies on 
the prevalence of antiphospholipid-antibody pos-
itivity. They indicate a prevalence of anticardio-
lipin-antibody positivity of 10% and a prevalence 
of lupus anticoagulant of 1% among healthy blood 
donors but do not provide a cutoff point for 
antiphospholipid-antibody positivity. This preva-
lence of antiphospholipid-antibody positivity would 
be higher than that among women with compli-
cations from pregnancy (6%) and similar to that 
among patients with venous thrombosis (10%) or 
myocardial infarction (11%). Obviously, the prev-
alence of antiphospholipid-antibody positivity de-
pends on an appropriate definition. The classifi-
cation criteria for the antiphospholipid syndrome 
recommend the use of either 40 GPL (IgG phos-
pholipid) or MPL (IgM phospholipid) units or the 
99th percentile of antiphospholipid-antibody titer 
in a reference group as the cutoff point for posi-
tivity.1 Unfortunately, 40 GPL or MPL units are 
not equivalent to the 99th percentile for most 
assays.2 Cutoff points recommended by manufac-
turers are often based on underpowered studies. 
We have shown in a population-based cohort of 
approximately 5000 participants that 3.2% had at 
least one antiphospholipid-antibody measurement 
(i.e., IgG or IgM anticardiolipin antibodies or 
IgG or IgM anti–β2-glycoprotein 1 antibodies) 
above the age-adjusted 99th percentile.3 Thus, 
before we discuss the prevalence of antiphospho-
lipid-antibody positivity, we should agree on a 
uniform definition of this condition.
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The authors reply: We agree with Ciavarella 
and Martinelli that, on the basis of the two stud-
ies published after our manuscript went to press, 
direct oral anticoagulants must be considered 
less effective than warfarin for the prevention of 
thrombosis in high-risk patients with APS.1,2 
While we would, for now, discourage the use of 
direct oral anticoagulants as a first-line throm-
bosis prevention strategy in high-risk patients 
with APS, we also think that ongoing (and pos-
sibly future) clinical trials should be considered 
before final conclusions are drawn about the role 
of direct oral anticoagulants in patients with APS. 
With respect to the comments of Riera-Mestre 
and Vidaller, we believe that catastrophic APS 
and TTP have many overlapping features and 
that both should be included under the umbrella 
of thrombotic microangiopathies. We agree that 
for patients with catastrophic APS who present 
with a TTP-like picture, plasma exchange could 
be very appropriate as a part of first-line combi-
nation treatment. Finally, we agree with Lackner 
and Müller-Calleja that without a universally ac-
cepted definition of antiphospholipid-antibody 
positivity, the prevalence of this condition in the 
general population will remain uncertain.
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